Neoplasms

Blood and Lymph Conditions

All Conditions

Symptoms and General Pathology

Rare Diseases

Leukemia

Leukemia, Myeloid

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Neoplasms by Histologic Type

Hematologic Diseases

Myeloproliferative Disorders

Bone Marrow Diseases

Chronic Disease

Disease Attributes

Myeloid Leukemia

Chronic Graft Versus Host Disease

Chronic Myeloid Leukemia

Chronic Myeloproliferative Disorders

All Drugs and Chemicals

Amino Acids

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)

The study included patients with CML who were previously treated with TKIs, who are relapsed/refractory to/intolerant of TKIs on third or later lines of therapy in the US.

Tyrosine Kinase Inhibitors (TKIs)

Novartis Pharmaceuticals

Retrospective, non-interventional observational cohort study conducted among patients with CML.

A retrospective, non-interventional cohort study was used to address the study objectives. A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database) to have a better understanding of real-world treatment patterns, HRU and healthcare costs among patients with CML treated with later lines of therapy (i.e., third line or later).

For Phase I, the IBM® MarketScan® Commercial Claims and Encounters and Medicare Supplemental Databases were used (commercial claims). The commercial claims covered the period from 01/01/2001 to 06/30/2019.

The study consisted of the following periods:

* The baseline period was defined as the 6-month period before the first line therapy initiation for CML.
* The observation period was defined as the period of at least 12 months from the first CML diagnosis to the end of data availability or end of health plan coverage, whichever occurs first; the observation period varied by patient.

Study Conducted Among Patients With CML

Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients With Chronic Myeloid Leukemia in Later Lines of Therapy

Number of patients across all lines of therapy were reported to evaluate treatment sequences among the patients.

Number of patients with the use of pre-treatment hydroxyurea were reported to evaluate treatment patterns in patients.

Number of patients Treatment received and initial dose at each line were reported to evaluate treatment patterns in patients.

Number of patients as per the calendar year of line of therapy initiation were reported to evaluate treatment patterns in patients.

Duration of the line of therapy was reported to evaluate treatment patterns in patients.

Treatment-free period among those with an observed subsequent line of therapy was reported to evaluate treatment patterns in patients.

Number of patients who discontinued treatment were reported to evaluate treatment patterns in patients.

Number of patients: All cause Health Resource Utilization were reported to estimate HRU among patients with three lines of therapy or more.

Healthcare costs among patients with three lines of therapy or more were reported.

Prevalence was defined as the number of cases alive per year of patients with CML who were currently or previously treated on later lines of therapy (third line or later), by calendar year from 2006 to 2018

Healthcare costs among patients with earlier lines of therapy were reported.

Number of patients: All cause Health Resource Utilization among patients with earlier lines of therapy were reported.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study Conducted Among Patients With CML	NCT05476562	Chronic Myeloid...	Tyrosine Kinase...	18 Years - 85 Years	Novartis
Study Conducted Among Patients With CML	NCT05476562	Chronic Myeloid...	Tyrosine Kinase...	18 Years - 85 Years	Novartis

Spots Global Cancer Trial Database for tyrosine kinase inhibitors,